CryoPort

CryoPort, Inc. engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers. It offers personalized medicine, immunotherapies, cellular therapies, CAR T-cell therapies, stem cell therapies, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, bio-pharmaceuticals, infectious substances, and other commodities that require continuous exposure to certain ranges of precision-controlled temperatures. The company was founded on May 25, 1990 and is headquartered in Brentwood, TN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CryoPort achieves record revenue, eyes growth in cell therapy logistics

CryoPort's Q4 2022 performance reflects robust revenue growth and strategic investments, positioning the company for further expansion in cell and gene therapy logistics.
While facing challenges in manufacturing capacity and supply chain, CryoPort's focus on revenue diversification and margin improvement initiatives strengthens its competitive position.
The company's outlook for 2023 is optimistic, with opportunities in supporting commercial therapies, market share expansion, and new product launches driving growth.

CryoPort (CYRX) reports strong Q1 revenue growth and eyes global expansion

CryoPort's Q1 performance reflects robust revenue growth and strategic advancements in logistics solutions.
While facing industry challenges and capacity constraints, CryoPort is leveraging opportunities for expansion and innovation.
The company's focus on acquisitions, partnerships, and market growth positions it well for future success.
Investments in capabilities and global expansion underscore CryoPort's commitment to driving revenue and operational excellence.

CryoPort reports Q2 revenue impact from China, remains confident in growth

CryoPort faces challenges from China's economic conditions but remains confident in its long-term growth drivers in the cell and gene therapy industry.
Strategic investments in technology, premium product positioning, and operational enhancements are key strengths driving future growth and competitiveness.
Navigating short-term challenges, seizing expansion opportunities, and leveraging synergies with MVE in China are crucial for CryoPort's future success.

CryoPort reports robust Q3 earnings, eyes growth in life sciences

CryoPort's Q3 results met expectations, showcasing growth in revenue and execution of its corporate strategy for long-term profitability.
The company's performance reflects strong demand, strategic acquisitions, and a focus on innovation and customer service.
While facing challenges like manufacturing capacity and rising costs, CryoPort remains well-positioned to capitalize on market opportunities.
With a clear outlook for future growth and a stable financial position, CryoPort is poised for continued success in the life sciences industry.

CryoPort reports strong revenue, eyes cell therapy growth in 2024

CryoPort's FY 2023 performance driven by service revenue and global clinical trial support.
Focused on revenue growth in cell and gene therapy industry, introducing innovative products.
Addressing challenges in market competition, revenue trends, and debt management.
Positioned for progressive advancement in 2024, capitalizing on market opportunities.

Cryoport maintains revenue guidance amidst challenges, eyes growth opportunities

Cryoport maintains revenue guidance despite Q1 challenges, focusing on growth drivers and cost-saving measures for improved financial performance.
Strong cash balance, collaborations with logistics companies, and ongoing revenue growth initiatives position Cryoport for future success.
Challenges in MVE business and biologistics revenue softness require attention, but opportunities lie in financial improvement and revenue growth drivers.
Anticipation of continuous progression in the second half and positive integration with CRYOPDP highlight growth prospects for Cryoport.

CryoPort reports strong Q2 revenue growth, eyes profitability by 2025

CryoPort's Q2 2024 performance reflects robust revenue growth and cost-saving initiatives.
While facing challenges in soft demand and market conditions, the company eyes growth opportunities.
Confidence in revenue guidance and proactive measures signal a strategic path to profitability.
Strengthening commercial revenue and upcoming facility openings position CryoPort for future growth.

CryoPort reports Q3 growth, focuses on profitability and cost reduction

CryoPort's Q3 performance showcased growth in Life Sciences Services and strategic initiatives to drive profitability.
Despite challenges in the life sciences sector and uneven market recovery in MVE division, CryoPort remains focused on cost reduction and long-term growth.
Opportunities lie in new product launches, high-value contract acquisitions, and maintaining financial strength post-election.
Overall, CryoPort's resilience and strategic focus position the company for sustained growth and profitability in the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cryoport, Inc. (NASDAQ:CYRX ) Q2 2024 Results Conference Call August 6, 2024 5:00 PM ET Company Participants Todd Fromer - Investor Relations-KCSA Strategic Communications Jerrell Shelton - Chief Executive Officer Mark Sawicki - Chief Scientific Officer Robert Stefanovich - Chief Financial Officer Conference Call Participants Paul Knight - KeyBanc David Larsen - BTIG Philip Song - Leerink Partners Matt Stanton - Jefferies Yuan Zhi - B. Riley David Saxon - Needham Operator [Abrupt Start] Cryoport Second Quarter 2024 Earnings Call.

Cryoport, Inc. (CYRX) Q2 2024 Earnings Call Transcript

CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.42 per share a year ago.

CryoPort, Inc. (CYRX) Reports Q2 Loss, Lags Revenue Estimates

LOS ANGELES, CA / ACCESSWIRE / August 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Begins Investigation Into Claims Against Cryoport Inc And Encourages Its Shareholders To Contact

Revenue improved sequentially across all businesses Commercial Cell & Gene Therapy revenue increased 51% year-over-year and 20% sequentially A record total of 684 global clinical trials supported as of June 30, 2024 Cost reduction initiatives anticipated to result in approximately $22 million of annualized cost savings and drive Cryoport towards its goal of profitable growth, as well as a return to positive Adjusted EBITDA in 2025 Company provides updated 2024 full-year revenue guidance of $225 to $235 million NASHVILLE, Tenn. , Aug. 6, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (Cryoport), a global leader in supply chain solutions for the life sciences, today announced financial results for its second quarter (Q2) and first half (H1) of 2024.

Cryoport Reports Second Quarter 2024 Financial Results

$200 million repurchase program authorized to repurchase common stock and/or convertible notes Repurchasing approximately $160 million of 0.75% Senior Notes due in 2026 at an 11.5% discount to par value Principal balance reduced to approximately $186.2 million NASHVILLE, Tenn. , Aug. 6, 2024 /PRNewswire/ --  Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in supply chain solutions for the life sciences, today announced that the Company's Board of Directors had authorized a repurchase program to purchase up to $200 million of the Company's common stock and/or convertible senior notes (the "2024 Repurchase Program").

Cryoport Announces $200 Million Repurchase Program and the Repurchase of $160 Million of Convertible Senior Notes

LOS ANGELES, CA / ACCESSWIRE / July 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Cryoport Incorporated Stockholders Are Encouraged By The Schall Law Firm To Make Contact During The Initiation Of An Allegations Investigation

NEW YORK, NY / ACCESSWIRE / July 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cryoport, Inc. ("Cryoport") (NASDAQ:CYRX) concerning possible violations of federal securities laws. On May 7, 2024, Cryoport announced "disappointing" first quarter earnings for fiscal 2024.

Levi & Korsinsky Investigates Possible Securities Fraud Violations by Cryoport, Inc. (CYRX)

Levi & Korsinsky Reminds Cryoport Investors of the Ongoing Investigation into Potential Violations of Securities Laws - CYRX

LOS ANGELES, CA / ACCESSWIRE / July 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Cryoport Incorporated Stockholders Are Invited By The Schall Law Firm To Reach Out Amidst The Initiation Of An Allegations Investigation

NEW YORK, NY / ACCESSWIRE / July 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cryoport, Inc. ("Cryoport") (NASDAQ:CYRX) concerning possible violations of federal securities laws. On May 7, 2024, Cryoport announced "disappointing" first quarter earnings for fiscal 2024.

ATTENTION Cryoport, Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights

Did Cryoport, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate- CYRX

NEW YORK, NY / ACCESSWIRE / July 23, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cryoport, Inc. ("Cryoport") (NASDAQ:CYRX) concerning possible violations of federal securities laws. On May 7, 2024, Cryoport announced "disappointing" first quarter earnings for fiscal 2024.

Levi & Korsinsky Reminds Shareholders of an Investigation into Cryoport, Inc. (CYRX) Regarding Potential Securities Fraud Allegations

NASHVILLE, Tenn. , July 23, 2024 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in supply chain solutions for the life sciences, today announced that the Company will report financial results for the second quarter ended June 30, 2024 on Tuesday, August 6, 2024 after U.S. markets close.

Cryoport to Report Second Quarter 2024 Financial Results on August 6, 2024

LOS ANGELES, CA / ACCESSWIRE / July 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Cryoport Incorporated Stockholders Are Invited By The Schall Law Firm To Reach Out Amidst Initiation Of An Allegations Investigation

LOS ANGELES, CA / ACCESSWIRE / July 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Stockholders Of Cryoport Incorporated Are Encouraged To Connect As The Schall Law Firm Begins An Investigation Into Allegations

LOS ANGELES, CA / ACCESSWIRE / July 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Cryoport Inc Shareholders Are Invited To Contact As The Schall Law Firm Initiates A Probe Into Claims

LOS ANGELES, CA / ACCESSWIRE / July 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Cryoport Inc Shareholders Are Called To Reach Out As The Schall Law Firm Begins An Inquiry Into Allegations

LOS ANGELES, CA / ACCESSWIRE / July 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Shareholders Of Cryoport Inc Are Invited To Contact As The Schall Law Firm Initiates An Investigation Into Claims

LOS ANGELES, CA / ACCESSWIRE / July 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Cryoport Inc Shareholders Are Encouraged To Reach Out As The Schall Law Firm Begins A Probe Into Allegations

LOS ANGELES, CA / ACCESSWIRE / July 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Cryoport Inc Shareholders Are Urged To Contact As The Schall Law Firm Initiates An Investigation Into Claims

CryoPort (CYRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

CryoPort (CYRX) Moves 26.7% Higher: Will This Strength Last?

LOS ANGELES, CA / ACCESSWIRE / July 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

As The Schall Law Firm Starts An Investigation Into Allegations, Shareholders Of Cryoport Inc Are Encouraged To Contact

LOS ANGELES, CA / ACCESSWIRE / July 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Shareholders Of Cryoport Inc Are Urged To Reach Out As The Schall Law Firm Begins A Probe Into Claims

LOS ANGELES, CA / ACCESSWIRE / July 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Cryoport Inc Shareholders Are Encouraged To Contact As The Schall Law Firm Initiates An Investigation Into Allegations

The heavy selling pressure might have exhausted for CryoPort (CYRX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

News for CryoPort Stock (CYRX)